Algorae Pharmaceuticals

Algorae (ASX: #1AI) has strengthened its balance sheet with a $3.99M capital raise. The funding supports growth across AlgoraeRx commercialisation and the AlgoraeOS R&D pipeline, with pro forma cash of ~$5.56M plus access to a $3.0M debt facility. View the announcement: app.sharelinktechnologies.com/announcement-p…

A key commercial milestone for Algorae (ASX: 1AI) The Company has lodged its first TGA registration application, which has now passed preliminary assessment and moved to evaluation. This is the first product from AlgoraeRx’s initial 7-product portfolio to enter the registration pathway - an important step toward potential commercial supply in Australia and New Zealand. View the full announcement: app.sharelinktechnologies.com/announcement-p… #ASX #1AI #Biotech #Pharma

Algorae (ASX: 1AI) is advancing validation of its AI-driven drug discovery platform, with a second screening program now underway with Peter MacCallum Cancer Centre. program will assess 24 high-priority drug combination candidates across four cancer cell lines, with key preclinical data expected within six months. This marks another important step in translating AlgoraeOS predictions into biological validation and supporting future development and commercial pathway discussions. 🔔View the full announcement: app.sharelinktechnologies.com/announcement-p… #1AI #ASXnews

Algorae was pleased to spend time on the ground with Cadila Pharmaceuticals Limited this week as part of its broader India manufacturing program. Engagements of this nature are important in informing execution planning, strengthening partner understanding and supporting the company’s commercial-readiness strategy. #1AI #Algorae #Pharma #Manufacturing #Execution

Algorae is in India this week as part of its ongoing work to support future commercial readiness. The visit is focused on partner engagement, manufacturing capability assessment and progressing key execution workstreams that underpin the company’s broader commercial pathway. Selected updates will be shared during the week where appropriate. For more, algoraepharma.com #1AI #Algorae #Pharma #Commercialisation #Execution

Algorae is in India this week as part of its ongoing work to support future commercial readiness. The visit is focused on partner engagement, manufacturing capability assessment and progressing key execution workstreams that underpin the company’s broader commercial pathway. Selected updates will be shared during the week where appropriate. For more, algoraepharma.com #1AI #Algorae #Pharma #Commercialisation #Execution

Algorae Pharmaceuticals (ASX: 1AI) was recently featured in @StockheadAU's Tony’s Takeaway, with Tony Locantro highlighting the Company’s AI-driven approach to identifying potential drug combinations and its commercial pathway through partnerships including Dr. Reddy’s. With AI-enabled drug repurposing and licensing potential in focus, Algorae continues to build momentum around a differentiated biotech strategy at the intersection of healthcare and technology. ▶️Watch it here: youtu.be/VQ36NVxM-tc?si… #ASX #1AI #Biotech #AI #HealthcareInvesting #SmallCaps

Algorae appoints senior pharma executive David Gulland as Non-Executive Director. Former GM of HPS Pharmacies, with experience in pharmaceutical distribution and healthcare services as Algorae scales its commercial business. Mr Gulland will also become COO of AlgoraeRx from 23 March. 🔔Read the full announcement: app.sharelinktechnologies.com/announcement-p… #Healthcare #Pharmaceuticals #ASX #Biotech

Algorae Pharma (#ASX: #1AI) finalises Commercial Licence & Supply Agreement with Cadila Pharmaceuticals to launch two news generic cardiovascular & metabolic medicines in Australian and New Zealand #ASXNews #Cardiology Read here: stocknessmonster.com/announcements/…

AI-enabled pharmaceutical company Algorae Pharma (#ASX: #1AI) is delighted to announce a non-deal corporate update presentation. stocknessmonster.com/announcements/…

@algoraepharma used AI to find 90 promising CBD drug combinations, with Associate Prof. Fatemeh Vafaee of UNSW AI Institute noting their technology outperforms global models. biotechdispatch.com.au/news/algorae-u…

AI-enabled pharmaceutical company Algorae Pharma (#ASX: #1AI) is delighted to announce receipt of in silico (supercomputer) drug synergy predictions from AlgoraeOS v2 - 90 combination drug targets predicted for further evaluation. #ASXNews #AI Read here: stocknessmonster.com/announcements/…

AI-enabled pharmaceutical company Algorae Pharma (#ASX: #1AI) has received a cash refund of $384,466.78 from the ATO under the R&D Tax Incentive program. #ASXNews #Biotech #Pharmaceuticals #Tech #AI

Algorae Pharma (#ASX : #1AI) is delighted to announce independent validation of its #AI-powered AlgoraeOS drug combination prediction platform. #ASXNews #biotech #pharma #tech Read here: stocknessmonster.com/announcements/…

Algorae Pharmaceuticals to Partner with Dr Reddy’s for Australian Supply of Chemotherapy Medicine #ASX #SmallCaps #1AI smallcaps.com.au/article/algora…

Algorae Pharma (#ASX: #1AI) is delighted to announce it has entered into a distribution agreement with global pharmaceutical leader Dr. Reddy’s Laboratories Ltd (#NYSE: $RDY) to supply the chemotherapy medicine Capecitabine into the Australian health market. Read here: stocknessmonster.com/announcements/…

Algorae Pharmaceuticals Limited (#ASX: #1AI) is delighted to announce the launch of AlgoraeOS Ver. 2 - a major upgrade to Algorae’s #AI drug discovery platform. Read here: stocknessmonster.com/announcements/…

Algorae Pharmaceuticals Driving Expansion with Innovation and Commercialisation ⁦@algoraepharma⁩ #1AI $1AI new.smallcaps.com.au/article/algora…

Algorae Pharmaceuticals (#ASX Code: #1AI) #ASXnews: Algorae September 2025 Quarterly Activities Report and Appendix 4C Cash Flow Statement. #AI #biotech #FDA #TGA Read here: stocknessmonster.com/announcements/…